دورية أكاديمية
Potent Killing of Pseudomonas aeruginosa by an Antibody-Antibiotic Conjugate.
| العنوان: | Potent Killing of Pseudomonas aeruginosa by an Antibody-Antibiotic Conjugate. |
|---|---|
| المؤلفون: | Kajihara KK; Department of Infectious Diseases, Genentech, Inc., South San Francisco, California, USA., Pantua H; Department of Infectious Diseases, Genentech, Inc., South San Francisco, California, USA., Hernandez-Barry H; Department of Biochemical and Cellular Pharmacology, Genentech, Inc., South San Francisco, California, USA., Hazen M; Department of Antibody Engineering, Genentech, Inc., South San Francisco, California, USA., Deshmukh K; Department of Biochemical and Cellular Pharmacology, Genentech, Inc., South San Francisco, California, USA., Chiang N; Department of Antibody Engineering, Genentech, Inc., South San Francisco, California, USA., Ohri R; Department of Protein Chemistry, Genentech, Inc., South San Francisco, California, USA., Castellanos ER; Department of Structural Biology, Genentech, Inc., South San Francisco, California, USA., Martin L; Department of BioMolecular Resources, Genentech, Inc., South San Francisco, California, USA., Matsumoto ML; Department of Structural Biology, Genentech, Inc., South San Francisco, California, USA., Payandeh J; Department of Infectious Diseases, Genentech, Inc., South San Francisco, California, USA.; Department of Antibody Engineering, Genentech, Inc., South San Francisco, California, USA.; Department of Structural Biology, Genentech, Inc., South San Francisco, California, USA., Storek KM; Department of Infectious Diseases, Genentech, Inc., South San Francisco, California, USA., Schneider K; Department of Antibody Engineering, Genentech, Inc., South San Francisco, California, USA., Smith PA; Department of Infectious Diseases, Genentech, Inc., South San Francisco, California, USA., Koehler MFT; Department of Medicinal Chemistry; Genentech, Inc., South San Francisco, California, USA., Tsai SP; Department of Biochemical and Cellular Pharmacology, Genentech, Inc., South San Francisco, California, USA., Vandlen R; Department of Protein Chemistry, Genentech, Inc., South San Francisco, California, USA., Loyet KM; Department of Biochemical and Cellular Pharmacology, Genentech, Inc., South San Francisco, California, USA., Nakamura G; Department of Antibody Engineering, Genentech, Inc., South San Francisco, California, USA., Pillow T; Department of Medicinal Chemistry; Genentech, Inc., South San Francisco, California, USA., Seshasayee D; Department of Antibody Engineering, Genentech, Inc., South San Francisco, California, USA., Kapadia SB; Department of Infectious Diseases, Genentech, Inc., South San Francisco, California, USA., Hazenbos WLW; Department of Infectious Diseases, Genentech, Inc., South San Francisco, California, USA. |
| المصدر: | MBio [mBio] 2021 Jun 29; Vol. 12 (3), pp. e0020221. Date of Electronic Publication: 2021 Jun 01. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 101519231 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2150-7511 (Electronic) NLM ISO Abbreviation: mBio Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Washington, D.C. : American Society for Microbiology |
| مواضيع طبية MeSH: | Anti-Bacterial Agents/*pharmacology , Antibodies, Monoclonal/*pharmacology , Macrophages/*drug effects , Macrophages/*immunology , Pseudomonas aeruginosa/*drug effects , Pseudomonas aeruginosa/*immunology, Animals ; Anti-Bacterial Agents/chemistry ; Anti-Bacterial Agents/immunology ; Antibodies, Monoclonal/chemistry ; Antibodies, Monoclonal/immunology ; Antibodies, Monoclonal/metabolism ; Drug Delivery Systems/methods ; Humans ; Macrophages/microbiology ; Mice ; Microbial Viability/drug effects ; Phagocytosis/drug effects ; Proof of Concept Study ; Pseudomonas Infections/drug therapy ; Pseudomonas Infections/immunology ; Pseudomonas aeruginosa/metabolism ; RAW 264.7 Cells ; Rats |
| مستخلص: | Pseudomonas aeruginosa causes life-threatening infections that are associated with antibiotic failure. Previously, we identified the antibiotic G2637, an analog of arylomycin, targeting bacterial type I signal peptidase, which has moderate potency against P. aeruginosa. We hypothesized that an antibody-antibiotic conjugate (AAC) could increase its activity by colocalizing P. aeruginosa bacteria with high local concentrations of G2637 antibiotic in the intracellular environment of phagocytes. Using a novel technology of screening for hybridomas recognizing intact bacteria, we identified monoclonal antibody 26F8, which binds to lipopolysaccharide O antigen on the surface of P. aeruginosa bacteria. This antibody was engineered to contain 6 cysteines and was conjugated to the G2637 antibiotic via a lysosomal cathepsin-cleavable linker, yielding a drug-to-antibody ratio of approximately 6. The resulting AAC delivered a high intracellular concentration of free G2637 upon phagocytosis of AAC-bound P. aeruginosa by macrophages, and potently cleared viable P. aeruginosa bacteria intracellularly. The molar concentration of AAC-associated G2637 antibiotic that resulted in elimination of bacteria inside macrophages was approximately 2 orders of magnitude lower than the concentration of free G2637 required to eliminate extracellular bacteria. This study demonstrates that an anti-P. aeruginosa AAC can locally concentrate antibiotic and kill P. aeruginosa inside phagocytes, providing additional therapeutic options for antibiotics that are moderately active or have an unfavorable pharmacokinetics or toxicity profile. IMPORTANCE Antibiotic treatment of life-threatening P. aeruginosa infections is associated with low clinical success, despite the availability of antibiotics that are active in standard microbiological in vitro assays, affirming the need for new therapeutic approaches. Antibiotics often fail in the preclinical stage due to insufficient efficacy against P. aeruginosa. One potential strategy is to enhance the local concentration of antibiotics with limited inherent anti-P. aeruginosa activity. This study presents proof of concept for an antibody-antibiotic conjugate, which releases a high local antibiotic concentration inside macrophages upon phagocytosis, resulting in potent intracellular killing of phagocytosed P. aeruginosa bacteria. This approach may provide new therapeutic options for antibiotics that are dose limited. |
| References: | J Intensive Care. 2014 Feb 18;2(1):10. (PMID: 25520826) Proc Natl Acad Sci U S A. 1985 Jan;82(2):488-92. (PMID: 3881765) J Infect Dis. 2017 Feb 15;215(suppl_1):S44-S51. (PMID: 28375513) J Clin Microbiol. 2003 May;41(5):2158-60. (PMID: 12734267) Nat Chem. 2016 Dec;8(12):1112-1119. (PMID: 27874860) Am J Respir Crit Care Med. 2013 Jul 1;188(1):69-76. (PMID: 23641973) Mol Microbiol. 1998 Jun;28(6):1103-19. (PMID: 9680202) J Bacteriol. 2019 Apr 22;201(18):. (PMID: 31010902) Lancet Infect Dis. 2018 Mar;18(3):318-327. (PMID: 29276051) Cell Rep. 2014 Jan 30;6(2):293-300. (PMID: 24412364) Clin Microbiol Rev. 2019 Aug 28;32(4):. (PMID: 31462403) Gene. 1995 May 26;158(1):15-22. (PMID: 7789804) J Immunol Methods. 1995 Oct 12;186(1):1-15. (PMID: 7561138) J Exp Med. 2012 Jul 2;209(7):1273-87. (PMID: 22734046) Lancet. 2019 Aug 31;394(10200):793-804. (PMID: 31478503) Nature. 2018 Sep;561(7722):189-194. (PMID: 30209367) Cell Host Microbe. 2015 Sep 9;18(3):307-19. (PMID: 26299432) Chest. 2016 Aug;150(2):415-25. (PMID: 27060725) J Bacteriol. 1988 Mar;170(3):1063-8. (PMID: 2830227) Nature. 2015 Nov 19;527(7578):323-8. (PMID: 26536114) Antimicrob Agents Chemother. 2017 May 24;61(6):. (PMID: 28373189) J Hosp Med. 2013 Oct;8(10):559-63. (PMID: 24022878) Nat Protoc. 2015 Nov;10(11):1820-41. (PMID: 26492139) Proc Natl Acad Sci U S A. 2018 Apr 3;115(14):3692-3697. (PMID: 29555747) J Med Chem. 2018 Feb 8;61(3):989-1000. (PMID: 29227683) MAbs. 2018 Oct;10(7):979-991. (PMID: 30102105) Am J Respir Crit Care Med. 2005 Jun 1;171(11):1209-23. (PMID: 15695491) Elife. 2019 Jun 25;8:. (PMID: 31237236) Annu Rev Med. 2018 Jan 29;69:191-207. (PMID: 29414262) Nat Biotechnol. 2008 Aug;26(8):925-32. (PMID: 18641636) J Infect Dis. 1982 Feb;145(2):217-23. (PMID: 6798136) Protein Expr Purif. 2005 May;41(1):207-34. (PMID: 15915565) Antimicrob Agents Chemother. 2019 May 24;63(6):. (PMID: 30910894) |
| فهرسة مساهمة: | Keywords: Pseudomonas aeruginosa; antibiotics; antibody-antibiotic conjugate; macrophage |
| المشرفين على المادة: | 0 (Anti-Bacterial Agents) 0 (Antibodies, Monoclonal) |
| تواريخ الأحداث: | Date Created: 20210601 Date Completed: 20211112 Latest Revision: 20211215 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC8262897 |
| DOI: | 10.1128/mBio.00202-21 |
| PMID: | 34061593 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2150-7511 |
|---|---|
| DOI: | 10.1128/mBio.00202-21 |